Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third-Party Payers Denied Class Certification in Neurontin, Vioxx Litigation

Executive Summary

Third-party payers may have a tough time getting class certification in suits alleging economic injury from drug purchases given recent rulings in Neurontin and Vioxx litigation
Advertisement

Related Content

Pfizer Must Pay Kaiser Cost-Difference Of Cheaper Drugs Under Neurontin Marketing Ruling
Third-Party Payers Strike Out in Suits Alleging Off-Label Promotion Injuries
Third-Party Payers Strike Out in Suits Alleging Off-Label Promotion Injuries
Neurontin Off-Label Suit: Plaintiffs’ Experts Claim Pfizer Slanted Studies
Vioxx Ruling May Curtail Health Plan Class Actions Against Drug Companies
Vioxx Ruling May Curtail Health Plan Class Actions Against Drug Companies
Warner-Lambert GMP Conviction Plays Role In Neurontin Case

Topics

Advertisement
UsernamePublicRestriction

Register

PS051107

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel